Risk of thrombosis and hemorrhage in patients with polycythemia vera and atrial fibrillation treated with prophylactic oral anticoagulants

Ann Hematol. 2016 Oct;95(11):1903-4. doi: 10.1007/s00277-016-2783-y. Epub 2016 Aug 12.

Authors

Ana Sofia de Freitas¹, Alberto Alvarez-Larrán²

Affiliations

¹ Hematology Department, Hospital del Mar-IMIM, UAB-UPF, Passeig Marítim 25-29, 08003, Barcelona, Spain.
² Hematology Department, Hospital del Mar-IMIM, UAB-UPF, Passeig Marítim 25-29, 08003, Barcelona, Spain. [email protected].

PMID: 27518531
DOI: 10.1007/s00277-016-2783-y

No abstract available

Publication types

Letter

MeSH terms

Acenocoumarol / therapeutic use*
Administration, Oral
Aged
Aged, 80 and over
Anticoagulants / therapeutic use*
Atrial Fibrillation / complications
Atrial Fibrillation / drug therapy*
Female
Follow-Up Studies
Hemorrhage / epidemiology
Hemorrhage / etiology*
Humans
Male
Middle Aged
Polycythemia Vera / complications
Polycythemia Vera / drug therapy*
Proportional Hazards Models
Risk Factors
Smoking / adverse effects
Smoking / epidemiology
Thrombophilia / drug therapy*
Thrombophilia / etiology
Thrombosis / epidemiology
Thrombosis / etiology*
Thrombosis / prevention & control
Warfarin / therapeutic use*

Substances

Anticoagulants
Warfarin
Acenocoumarol